Published in Cancer Weekly, February 25th, 2003
Wyeth has exclusively sublicensed to GTx patents covering VSV as cytolytic agents for use with proprietary VSV-based products of GTx. In return, Wyeth has an option to commercially license GTx's VSV-based anti-HIV product, GTx-v311. GTx has also granted to Wyeth a nonexclusive license to GTx's VSV vaccine technology, where recombinant VSV is used as vector for delivery of vaccine antigens.
GTx, Inc., is currently developing VSV technologies for use as targeted viral cytolytic agents...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.